Vesugen results: what to expect and when
An experimental blood-vessel peptide with unclear benefits and poorly defined safety.
Also called: Vezugen, KED, Lys-Glu-Asp, T-38.
Khavinson bioregulator peptides · Synthetic vascular tripeptide.
12 clinical papers and 2 patent examples found. Reports may include the same participants; these are not 14 independent trials.
Key studies
- Truck drivers and stress: Combined Pinealon and Vesugen had the strongest reported changes in stress-related questionnaire scores. (source)
- Blood flow after leg-artery surgery: Authors reported better clinical and ultrasound measures after Vesugen. (source)
- Vascular report with conflicting indexing: The abstract reports improved penile blood flow; the title and abstract do not match. (source)
- Older adults with several illnesses: Aging-marker changes came with prooxidant activity and fewer circulating CD34+ cells. (source)
- Work-ability index report: Combined cytogens reportedly improved work-ability measures; Vesugen-specific effects cannot be isolated. (source)
- Comparison of aging interventions: Vesugen plus Pinealon had the strongest reported changes in biological-age indicators. (source)
Related to Vesugen
- Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
- Pinealon: A peptide with unproven brain benefits and no established injection dose.
- Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
- Thymogen: A Russian peptide used for immune problems, with negative cancer trials.
- Cortagen: A four-amino-acid brain peptide backed mainly by animal work and unverified patent claims.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US Food and Drug Administration · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, National Library of Medicine
- Drugs@FDA: FDA-Approved Drugs, US Food and Drug Administration
- Heart Attack, National Library of Medicine
- Sepsis, National Library of Medicine
- Stroke, National Library of Medicine
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.